对标题为“一线纳武利尤单抗联合伊匹木单抗与化疗治疗转移性非小细胞肺癌：CheckMate 9LA的更新结果”的致编辑信的回复 - Suppr

Suppr

超能文献

Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA".

作者信息

Paz-Ares Luis G, Carbone David P

机构信息

Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain.

Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

出版信息

J Thorac Oncol. 2023 Sep;18(9):e102-e103. doi: 10.1016/j.jtho.2023.05.022.

DOI:10.1016/j.jtho.2023.05.022

PMID:37599049

Abstract

摘要

相似文献

Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA".对标题为“一线纳武利尤单抗联合伊匹木单抗与化疗治疗转移性非小细胞肺癌：CheckMate 9LA的更新结果”的致编辑信的回复

J Thorac Oncol. 2023 Sep;18(9):e102-e103. doi: 10.1016/j.jtho.2023.05.022.

First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA.一线纳武利尤单抗联合伊匹木单抗与化疗治疗转移性非小细胞肺癌：CheckMate 9LA研究的更新结果

J Thorac Oncol. 2023 Sep;18(9):e101-e102. doi: 10.1016/j.jtho.2022.11.024.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.CheckMate 9LA 中晚期非小细胞肺癌一线纳武利尤单抗联合伊匹单抗加两个周期化疗的亚组分析：亚洲患者数据。

Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19.

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.CheckMate 227 研究部分 1：一线纳武利尤单抗联合伊匹木单抗治疗伴基线脑转移的转移性非小细胞肺癌患者的系统和颅内结局。

J Thorac Oncol. 2023 Aug;18(8):1055-1069. doi: 10.1016/j.jtho.2023.04.021. Epub 2023 May 3.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.一线纳武利尤单抗联合伊匹单抗加两个周期化疗对比单独化疗（四个周期）治疗转移性非小细胞肺癌：CheckMate 9LA 研究 2 年患者报告结局。

Eur J Cancer. 2023 Apr;183:174-187. doi: 10.1016/j.ejca.2023.01.015. Epub 2023 Jan 28.

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.一线纳武利尤单抗联合伊匹单抗治疗晚期 NSCLC：CheckMate 227 亚组分析在亚洲患者中的结果。

ESMO Open. 2022 Feb;7(1):100394. doi: 10.1016/j.esmoop.2022.100394. Epub 2022 Feb 12.

Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.在美国，nivolumab 联合 ipilimumab 加两个周期铂类双药化疗对比单纯铂类双药化疗一线治疗 IV 期或复发性非小细胞肺癌的成本效果分析。

J Med Econ. 2022 Jan-Dec;25(1):660-668. doi: 10.1080/13696998.2022.2048573.

Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌的成本效果分析。

JAMA Netw Open. 2021 May 3;4(5):e218787. doi: 10.1001/jamanetworkopen.2021.8787.

Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.纳武利尤单抗联合伊匹木单抗对比化疗作为晚期非小细胞肺癌一线治疗的成本效益

Int Immunopharmacol. 2023 Jan;114:109589. doi: 10.1016/j.intimp.2022.109589. Epub 2022 Dec 19.

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.一线纳武利尤单抗联合伊匹木单抗治疗转移性非小细胞肺癌患者的安全性：CheckMate 227、CheckMate 568和CheckMate 817的汇总分析

J Thorac Oncol. 2023 Jan;18(1):79-92. doi: 10.1016/j.jtho.2022.08.014. Epub 2022 Aug 30.

引用本文的文献

Immunotherapy and the Tumor Microenvironment in Brain Metastases from Non-Small Cell Lung Cancer: Challenges and Future Directions.非小细胞肺癌脑转移中的免疫疗法与肿瘤微环境：挑战与未来方向

Curr Oncol. 2025 Mar 16;32(3):171. doi: 10.3390/curroncol32030171.

Dramatic Metabolic Response to Dual ICI With Chemotherapy in Low PD-L1 NSCLC Case.低PD-L1非小细胞肺癌病例中双重免疫检查点抑制剂联合化疗的显著代谢反应

Respirol Case Rep. 2025 Mar 16;13(3):e70150. doi: 10.1002/rcr2.70150. eCollection 2025 Mar.

Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.免疫检查点抑制剂联合铂类化疗对比铂类化疗联合或不联合贝伐珠单抗用于治疗老年人晚期非小细胞肺癌的一线治疗。

Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495.

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.博特西单抗联合巴替利单抗治疗复发/难治性微卫星稳定转移性结直肠癌：一项 1 期临床试验。

Nat Med. 2024 Sep;30(9):2558-2567. doi: 10.1038/s41591-024-03083-7. Epub 2024 Jun 13.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验